Internal Medicine, Endocrinology, Diabetes, & Metabolism · Slidell, LA
NPI
1740281708
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
5
Hospital affiliations
2250 Gause Blvd E, Suite 200
Slidell, LA, 70461
Phone (985) 259-4318
Medicare paid, 2024
$56K
1,057 services
Medicare patients, 2024
450
Average age 74
Drug cost, 2024
$2.0M
5,854 prescriptions
Company payments, 2025
$1,277
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Madelyn C Wiegand was code 99214 (office e&m - established), 454 times for 206 patients. In total Madelyn C Wiegand billed 1,057 services in 7 codes, and Medicare paid $56K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-04-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 454 | 206 | $73.66 | $33K |
| 99213 Office E&M - Established | Office | 347 | 238 | $50.33 | $17K |
| 82962 Clinical Chemistry | Office | 186 | 111 | $3.10 | $577 |
| 99204 Office E&M - New | Office | 31 | 31 | $94.31 | $2,924 |
By year: 2022 $68K for 1,269 services; 2023 $65K for 1,178 services; 2024 $56K for 1,057 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 186 | 111 | $3.10 | $577 |
Medicare prescription drug claims, 2024
In 2024, the drug Madelyn C Wiegand prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 583 prescriptions and refills. In total Madelyn C Wiegand wrote 5,854 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 583 | 1,361 | 123 | $46K |
| Levothyroxine Sodium Generic | 371 | 963 | 90 | $2,991 |
| Unithroid Levothyroxine Sodium | 367 | 994 | 98 | $16K |
| Metformin Hcl Er Metformin Hcl | 314 | 812 | 86 | $3,962 |
| Mounjaro Tirzepatide | 267 | 333 | 43 | $344K |
| Rosuvastatin Calcium Generic | 255 | 630 | 68 | $3,515 |
| Farxiga Dapagliflozin Propanediol | 206 | 310 | 32 | $167K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 184 | 338 | 42 | $192K |
| Jardiance Empagliflozin | 172 | 288 | 42 | $164K |
| Levoxyl Levothyroxine Sodium | 159 | 384 | 36 | $7,557 |
| Trulicity Dulaglutide | 151 | 221 | 32 | $210K |
| Ozempic Semaglutide | 126 | 157 | 23 | $144K |
| Novolog Flexpen Insulin Aspart | 119 | 194 | 38 | $25K |
| Atorvastatin Calcium Generic | 111 | 303 | 37 | $773 |
| Pravastatin Sodium Generic | 107 | 275 | 28 | $1,406 |
Brand drugs: 3,245 claims; generic drugs: 2,427 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Madelyn C Wiegand $1,277 ($1,277 in general payments such as food, travel and fees) from 20 companies. The largest payer was Novo Nordisk Inc with $171.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 9 | $171 |
| Amgen Inc. AMGN | 9 | $138 |
| Amneal Pharmaceuticals LLC AMRX | 9 | $137 |
| Abbvie Inc. ABBV | 6 | $106 |
| Xeris Pharmaceuticals, Inc. | 5 | $87.09 |
| Lilly USA, LLC LLY | 4 | $73.23 |
| Dexcom, Inc. DXCM | 3 | $69.62 |
| Corcept Therapeutics CORT | 4 | $66.35 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $56.57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $54.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.